Numerai GP LLC Has $1.09 Million Stock Holdings in Alignment Healthcare, Inc. (NASDAQ:ALHC)

Numerai GP LLC trimmed its holdings in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) by 10.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,143 shares of the company’s stock after selling 11,519 shares during the quarter. Numerai GP LLC owned 0.05% of Alignment Healthcare worth $1,093,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Alignment Healthcare during the 4th quarter worth approximately $55,000. RiverPark Advisors LLC bought a new position in Alignment Healthcare during the fourth quarter worth $106,000. Tower Research Capital LLC TRC increased its stake in Alignment Healthcare by 146.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company’s stock valued at $119,000 after purchasing an additional 6,286 shares in the last quarter. Ballentine Partners LLC bought a new stake in Alignment Healthcare in the fourth quarter valued at $121,000. Finally, Aigen Investment Management LP bought a new stake in Alignment Healthcare in the fourth quarter valued at $129,000. 86.19% of the stock is owned by institutional investors.

Insider Buying and Selling at Alignment Healthcare

In other news, CEO John E. Kao sold 554,713 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.53, for a total value of $8,614,692.89. Following the completion of the sale, the chief executive officer now directly owns 4,733,664 shares of the company’s stock, valued at approximately $73,513,801.92. This trade represents a 10.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Andreas P. Wagner sold 7,632 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $16.40, for a total transaction of $125,164.80. Following the completion of the sale, the insider now directly owns 223,474 shares of the company’s stock, valued at approximately $3,664,973.60. This represents a 3.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,076,977 shares of company stock valued at $33,671,411 in the last quarter. Company insiders own 7.00% of the company’s stock.

Alignment Healthcare Price Performance

ALHC stock opened at $14.05 on Wednesday. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.60 and a current ratio of 1.60. Alignment Healthcare, Inc. has a 52 week low of $6.82 and a 52 week high of $21.06. The firm’s fifty day moving average is $17.30 and its 200 day moving average is $14.50. The firm has a market cap of $2.78 billion, a P/E ratio of -18.25 and a beta of 1.32.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.07. The business had revenue of $926.93 million during the quarter, compared to analysts’ expectations of $889.83 million. Alignment Healthcare had a negative net margin of 5.84% and a negative return on equity of 108.69%. The firm’s revenue for the quarter was up 47.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.25) EPS. Research analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALHC has been the topic of a number of analyst reports. Robert W. Baird upped their target price on shares of Alignment Healthcare from $17.00 to $22.00 and gave the stock an “outperform” rating in a report on Tuesday, April 15th. Stifel Nicolaus upped their price target on shares of Alignment Healthcare from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday, April 8th. Piper Sandler increased their price target on shares of Alignment Healthcare from $14.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. UBS Group increased their price target on shares of Alignment Healthcare from $16.00 to $17.00 and gave the stock a “neutral” rating in a report on Friday, May 2nd. Finally, Stephens reissued an “overweight” rating and issued a $17.00 price target on shares of Alignment Healthcare in a report on Monday, February 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.17.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.